Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeStance Health (LFST) Assets (2021 - 2025)

Historic Assets for LifeStance Health (LFST) over the last 5 years, with Q3 2025 value amounting to $2.1 billion.

  • LifeStance Health's Assets rose 194.64% to $2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year increase of 194.64%. This contributed to the annual value of $2.1 billion for FY2024, which is 39.47% up from last year.
  • Per LifeStance Health's latest filing, its Assets stood at $2.1 billion for Q3 2025, which was up 194.64% from $2.1 billion recorded in Q2 2025.
  • LifeStance Health's Assets' 5-year high stood at $2.2 billion during Q3 2023, with a 5-year trough of $1.9 billion in Q2 2021.
  • In the last 5 years, LifeStance Health's Assets had a median value of $2.1 billion in 2023 and averaged $2.1 billion.
  • Its Assets has fluctuated over the past 5 years, first surged by 1280.48% in 2022, then tumbled by 308.61% in 2024.
  • Quarter analysis of 5 years shows LifeStance Health's Assets stood at $1.9 billion in 2021, then grew by 12.8% to $2.2 billion in 2022, then dropped by 2.94% to $2.1 billion in 2023, then increased by 0.39% to $2.1 billion in 2024, then rose by 1.45% to $2.1 billion in 2025.
  • Its Assets stands at $2.1 billion for Q3 2025, versus $2.1 billion for Q2 2025 and $2.1 billion for Q1 2025.